肺癌类器官在精准治疗中的应用  

Application of lung cancer organoids in precision medicine

作　　者：殷悦 马秀清[2] 许阳[2] 戴钰[2] 陈良安[2] Yin Yue;Ma Xiuqing;Xu Yang;Dai Yu;Chen Liang′an(Chinese PLA Medical School,Beijing 100853,China;Department of Pulmonary and Critical Care Medicine,First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军医学院研究生院,北京100853 [2]解放军总医院第一医学中心呼吸与危重症医学科,北京100853

出　　处：《中华结核和呼吸杂志》2024年第11期1113-1120,共8页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：肺癌是全球癌症相关死亡的主要原因之一,迫切需要开发更可靠的临床前模型以便确定有效的治疗方法。并且,肺癌在个体间显示出显著的异质性,需要精准治疗来实现全程管理。肺癌类器官直接来源于患者肿瘤组织或细胞,保留了肿瘤原始的组织结构和分子特征,有望成为研究耐药机制和预测患者疗效的良好模型。本文详细阐述了患者来源肺癌类器官的构建方法和精准治疗中的应用,并讨论了目前类器官研究的局限性和未来的前景。Lung cancer is one of the leading causes of cancer-related death worldwide,and there is an urgent need to develop more reliable preclinical models to identify effective treatments.Moreover,lung cancer exhibits significant heterogeneity between individuals and requires precision medicine to achieve comprehensive management.Lung cancer organoids(LCOs)are derived from patients′tumor tissues or tumor cells,which enables them to faithfully recapitulate in vivo tumor characteristics and heterogeneity,providing a promising platform to study drug resistance mechanisms and predict therapy efficacy.Here,we described the construction of LCOs and their application in precision therapy.We also discussed the limitations and prospects of current organoids research.

关 键 词：类器官 精准治疗 分子特征 患者来源 肺癌 耐药机制 全程管理 肿瘤组织 

分 类 号：R734.2[医药卫生—肿瘤]